Payment overview · 2025
General Payments
$36.84
2 reported records · 2 companies
Healthcare provider profile · identity verified
Christopher A. Baltes, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT WAYNE, IN · NPI 1992090971
Verified facts
What the public records show
CMS Open Payments records show Christopher A. Baltes, MD received $36.84 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 52.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.30 | 52.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.54 | 47.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $36.84 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1475 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1192 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 783 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 654 | 62 |
| Furosemide | Furosemide | 625 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 572 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 516 | 65 |
| Metformin Hcl | Metformin Hcl | 507 | 58 |
| Lisinopril | Lisinopril | 483 | 81 |
| Sertraline Hcl | Sertraline Hcl | 456 | 49 |
| Famotidine | Famotidine | 452 | 27 |
| Donepezil Hcl | Donepezil Hcl | 441 | 22 |
| Eliquis | Apixaban | 436 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 422 | 93 |
| Fluoxetine Hcl | Fluoxetine Hcl | 373 | 29 |
| Carvedilol | Carvedilol | 350 | 39 |
| Omeprazole | Omeprazole | 345 | 66 |
| Gabapentin | Gabapentin | 340 | 56 |
| Allopurinol | Allopurinol | 327 | 42 |
| Buspirone Hcl | Buspirone Hcl | 322 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 316 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 310 | 36 |
| Trazodone Hcl | Trazodone Hcl | 306 | 41 |
| Memantine Hcl | Memantine Hcl | 292 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 72 |
| Losartan Potassium | Losartan Potassium | 268 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 268 | 15 |
| Mirtazapine | Mirtazapine | 254 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 235 | 33 |
| Simvastatin | Simvastatin | 231 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 219 | 19 |
| Potassium Chloride | Potassium Chloride | 202 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 190 | 46 |
| Prednisone | Prednisone | 189 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 30 |
| Meloxicam | Meloxicam | 168 | 32 |
| Spironolactone | Spironolactone | 168 | 19 |
| Celecoxib | Celecoxib | 164 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 15 |
| Bumetanide | Bumetanide | 158 | 17 |
| Gemtesa | Vibegron | 155 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 149 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 41 |
| Xarelto | Rivaroxaban | 131 | suppressed |
| Jardiance | Empagliflozin | 129 | 23 |
| Risperidone | Risperidone | 126 | suppressed |
| Finasteride | Finasteride | 125 | 19 |
| Metformin Hcl Er | Metformin Hcl | 116 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 113 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 110 | suppressed |
| Januvia | Sitagliptin Phosphate | 108 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 46 |
| Levetiracetam | Levetiracetam | 107 | suppressed |
| Atenolol | Atenolol | 105 | 30 |
| Ezetimibe | Ezetimibe | 105 | 14 |
| Glipizide | Glipizide | 100 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 100 | 24 |
| Cephalexin | Cephalexin | 99 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 99 | 28 |
| Myrbetriq | Mirabegron | 94 | suppressed |
| Bupropion Xl | Bupropion Hcl | 90 | 26 |
| Alendronate Sodium | Alendronate Sodium | 88 | 20 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 87 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 83 | suppressed |
| Aripiprazole | Aripiprazole | 80 | 11 |
| Divalproex Sodium | Divalproex Sodium | 80 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 78 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 76 | suppressed |
| Folic Acid | Folic Acid | 75 | suppressed |
| Lorazepam | Lorazepam | 73 | 16 |
| Pentoxifylline | Pentoxifylline | 73 | suppressed |
| Azithromycin | Azithromycin | 69 | 55 |
| Memantine Hcl Er | Memantine Hcl | 69 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 69 | suppressed |
| Haloperidol | Haloperidol | 68 | suppressed |
| Olanzapine | Olanzapine | 68 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 67 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 14 |
| Valacyclovir | Valacyclovir Hcl | 65 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 54 |
| Repaglinide | Repaglinide | 60 | 12 |
| Digoxin | Digoxin | 59 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 42 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 20 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 56 | suppressed |
| Budesonide Dr | Budesonide | 55 | suppressed |
| Tradjenta | Linagliptin | 54 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 15 |
| Cimetidine | Cimetidine | 52 | suppressed |
| Dapsone | Dapsone | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 52 | suppressed |
| Anastrozole | Anastrozole | 50 | suppressed |
| Nystatin | Nystatin | 49 | 26 |
| Telmisartan | Telmisartan | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Alprazolam | Alprazolam | 47 | 16 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 14 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 13 |
| Methylprednisolone | Methylprednisolone | 45 | 41 |
| Clonazepam | Clonazepam | 43 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Methotrexate | Methotrexate Sodium | 42 | suppressed |
| Cilostazol | Cilostazol | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 30 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 12 |
| Baclofen | Baclofen | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Verapamil Sr | Verapamil Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | 12 |
| Febuxostat | Febuxostat | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Testosterone | Testosterone | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sulindac | Sulindac | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36.84 · 2 records | Novo Nordisk Inc | JARDIANCE, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error